Bloomage BioTechnology (688363) Q2 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was ¥2.26 billion, down 19.57% year-over-year, mainly due to a decline in skin science innovation business income.

• Net profit attributable to shareholders was ¥221 million, a 35.38% decrease year-over-year.

• The company focused on organizational reform, cost control, and R&D prioritization, with a significant reduction in sales expenses and a shift to efficiency-driven brand communication.

• R&D investment increased, with a focus on high-barrier raw materials and medical terminal products.

• The company maintained a strong position in the hyaluronic acid industry, with international expansion and new product launches.

Financial highlights

• Operating income: ¥2.26 billion, down 19.57% year-over-year.

• Net profit attributable to shareholders: ¥221 million, down 35.38% year-over-year.

• Net profit after non-recurring items: ¥174 million, down 45.00% year-over-year.

• Operating cash flow: ¥218 million, down 17.49% year-over-year.

• Gross margin: 70.99%.

• Basic and diluted EPS: ¥0.46, down 35.21% year-over-year.

Outlook and guidance

• The company will continue to focus on technological innovation, optimize business structure, and improve operational efficiency.

• R&D will remain concentrated on high-barrier raw materials and medical terminal products, with further optimization of R&D expenses and efficiency expected.

• The company aims to leverage its synthetic biology platform for broader applications and high-quality growth.